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1. INTRODUCTION {#mgg3827-sec-0005}
===============

Hypospadias is a condition in which the opening of the urethra is found on the ventral surface of the penis, and is one of the most common congenital malformations. The prevalence of hypospadias varies greatly, ranging from 1 in 125 to 250 male live births in different countries (Singh et al., [2018](#mgg3827-bib-0025){ref-type="ref"}). It may occur as an isolated defect or may be associated with other genital malformations (e.g., micropenis, cryptorchidism in one or both sides, and bifid scrotum) or with other organ malformations. According to the severity and the location of the urethral opening, hypospadias is often classified as anterior, middle, or posterior (van der Zanden et al., [2012](#mgg3827-bib-0030){ref-type="ref"}). External genital malformations, as physical indicators of maleness, can have different physiological and psychological effects on children. Early surgical treatment is needed, and the different causes of hypospadias have different surgical requirements. Therefore, it is very necessary to identify the precise cause of hypospadias.

The etiology of hypospadias is complicated, and is thought to be related to genetic, endocrine, and environmental factors (Shih & Graham, [2014](#mgg3827-bib-0024){ref-type="ref"}). To date, monogenic and chromosomal causes of hypospadias account for about 30% of all cases, indicating the significant role of genetics in the development of hypospadias (Sagodi, Kiss, Kiss‐Toth, & Barkai, [2014](#mgg3827-bib-0023){ref-type="ref"}). In addition, hypospadias has been described in over 200 syndromes (Blaschko, Cunha, & Baskin, [2012](#mgg3827-bib-0004){ref-type="ref"}). There are three main molecular features of male external genitalia formation: (a) gonadal differentiation, (b) gonadal development, and (c) dependence on endocrine and environmental factors. In the early stages of genital tubercle development, a gonadal differentiation pathway is among the activated pathways, and relies on HOX signaling, WNT/β‐catenin signaling, Hedgehog signaling, and bone morphogenetic protein (*BMP*) signaling (Y. Chen et al., [2018](#mgg3827-bib-0011){ref-type="ref"}; Kojima, Kohri, & Hayashi, [2010](#mgg3827-bib-0018){ref-type="ref"}). Other genes have been reported to be associated with hypospadias including sex‐determining region Y (*SRY*) (OMIM 480,000), homeobox D13 (*HOXD13*) (OMIM 142,989), friend of *GATA2* (*FOG2*) (OMIM 603,693), and GATA‐type zinc finger protein 4 (*GATA4*) (OMIM 600,576) (Brauner et al., [2016](#mgg3827-bib-0006){ref-type="ref"}; Carmichael et al., [2013](#mgg3827-bib-0009){ref-type="ref"}). Moreover, steroid‐5‐α‐reductase (*SRD5A*) (OMIM 607,306) converts testosterone into dihydrotestosterone (DHT), which binds to the androgen receptor (*AR*) (OMIM 313,700) and thereby stimulates the formation of the external genitalia.

The etiology of hypospadias in most patients remains unknown, indicating that there are new candidate genes that have not yet been discovered. The aim of this study was to identify the pathogenic genes responsible for hypospadias in a cohort of 130 patients using next‐generation sequencing (NGS) of a targeted gene panel. The gene panel contained 105 hypospadias‐associated genes, some of which were not previously reported in patients but were implicated due to their known roles in gonadal and urethral development in male mice.

2. MATERIALS AND METHODS {#mgg3827-sec-0006}
========================

2.1. Ethical compliance {#mgg3827-sec-0007}
-----------------------

This study was ratified by the Ethics Committee of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Informed consent from the parents or guardians of the subjects was obtained for all examinations.

2.2. Patients {#mgg3827-sec-0008}
-------------

From May 2017 to March 2018, a total of 130 Chinese patients of age 6 months to 18 years old with variable degrees of hypospadias were enrolled in our cohort to screen for pathogenic genes. All patients were raised as males and had a 46, XY karyotype and SRY gene. Certain patients had hypospadias accompanied by additional genitourinary abnormalities including micropenis, inguinal hernia, unilateral or bilateral cryptorchidism, or bifid scrotum. All patients were being examined at Ruijin Hospital and Renjin Hospital affiliated with Shanghai Jiaotong University School of Medicine.

The clinical evaluation of the enrolled patients included chief complaints, history of present illness, birth history, personal history, family history, maternal pregnancy history, previous operation history, hormone therapy history, living environment, and history of contact with environmental pollutants. Physical examination involved measurement of height, weight, extended penis length, testicular volume size, and male genital evaluation.

Laboratory and imaging examinations included chromosome karyotype analysis and detection of *SRY* fragments, and measurement of blood biochemical and endocrine‐related hormone levels (luteinizing hormone, follicle‐stimulating hormone, testosterone, DHT, inhibin B, etc.). Gonadotropin‐releasing hormone and human chorionic gonadotropin stimulation tests and gonadal ultrasound were performed in some of the patients.

Informed consent was obtained from each participating individual or their parents. This study was approved by the Ethics Committee of Ruijin Hospital.

2.3. Targeted gene panel {#mgg3827-sec-0009}
------------------------

Our hypospadias panel included 105 genes (Table [1](#mgg3827-tbl-0001){ref-type="table"}) involved in gonadal development, gonadal differentiation, and/or specific syndromes. The targeted genes were obtained by referencing the GeneCards database and by entering the keywords "hypospadias," "disorders of sex development," or "gonad genesis" in PubMed.

###### 

List of 105 genes in gene panel

  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------
  Gonadal differentiation          HOX signaling                                                                                                                                                                                                                                       HOXA4, HOXA13, HOXB6, HOXD13
  Hedgehog signaling               DHH, GLI3, SHH                                                                                                                                                                                                                                      
  FGF signaling                    FGF8, FGF10, FGFR1, FGFR2, FGFR3                                                                                                                                                                                                                    
  SOX signaling                    SOX2, SOX3, SOX9, SOX10                                                                                                                                                                                                                             
  BMP signaling                    BMP4, BMP7                                                                                                                                                                                                                                          
  Other                            CBX2, CHD7, DGKK, DMRT1, GATA4, GATA5, MAP3K1, NR0B1, NR5A1, RSPO1, SRY, Wnt5a, WT1, ZFPM2                                                                                                                                                          
  Gonadal development              Androgen‐related                                                                                                                                                                                                                                    AR, FKBP4, FOXA1, FLNA, HSD17B3, HSD3B2, SRD5A2
  Estrogen‐related                 ATF3, CTGF, ESR1, ESR2, ZEB2                                                                                                                                                                                                                        
  Adrenal insufficiency            CYP11A1                                                                                                                                                                                                                                             
  Other                            AKR1C2, AKR1C4, AMH, ARX, ATRX, CYB5A, LHCGR, MAMLD1, POR, STAR                                                                                                                                                                                     
  Central causes of hypogonadism   GNRHR, KAL1, LHX3, PROKR2, PROP1, TAC3, WDR11                                                                                                                                                                                                       
  Toxin metabolism                 CYP1A1, GSTM1, GSTT1                                                                                                                                                                                                                                
  Syndrome                         KANSL1, MID1, MID2, SPECC1L                                                                                                                                                                                                                         
  Other                            BBOX1, BNC2, CUL4B, FOXC1, FRAS1, GPC3, HBQ1, HYSP3, HYSP4, IGF2, INSL3, IRF6, KIF7, LHFPL5, LHX9, LIG4, LMNA, MECP2, MECP2, NLGN4X, PITX2, PCNT, PAX2, PAX6, RAD21, RPL35A, SRCAP, SNAP29, SETD5, SALL1, TRIM17, TP63, TMLHE, TDRD7, TBX22, WWOX   
  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------
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2.4. Next‐generation sequencing {#mgg3827-sec-0010}
-------------------------------

Genomic DNA was extracted from the patients\' peripheral blood lymphocytes using a Qiagen kit according to the manufacturer\'s protocol. Total genomic DNA was sequenced using our targeted panel covering 105 relevant genes. Eight hundred nanograms of genomic DNA was randomly fragmented into 150--250 bp fragments using a Biorupter, and DNA libraries were prepared using the KAPA LTP Library Preparation kit and PCR amplification of the fragmented DNA. iGeneTech was used to synthesize the oligo pool containing 105 gene coding regions, which were then PCR amplified and transcribed to synthesize RNA probes. The sample DNA library was then hybridized with the RNA probes for 24 hr at 65°C and the target fragment was captured by binding to the specific probe after PCR amplification. The final products were sequenced using the Illumina‐MiSeq sequencing platform.

2.5. Data analysis and assessment of variants {#mgg3827-sec-0011}
---------------------------------------------

Variants were checked for quality and depth, then filtered to include those with \<1% minor allele frequency according to the GnomAD (East Asian). The NGS results were compared with the human genome reference sequence for single nucleotide polymorphism (SNP) and InDel annotation analysis. Mutations predicted to disrupt protein structure were identified using in silico tools, such as Mutation Taster, Polyphen‐2, and SIFT. The ACMG standards and reference to the NCBI, ClinVar, and HGMD databases were used to classify the mutations into five categories: pathogenic, likely pathogenic (LP), variants of uncertain significance (VUS), likely benign, or benign (Amendola et al., [2016](#mgg3827-bib-0002){ref-type="ref"}). Mutations were verified by Sanger sequencing. Finally, we analyzed the correlations between clinical phenotypes and genotypes.

3. RESULTS {#mgg3827-sec-0012}
==========

3.1. Genetic variants identified by NGS {#mgg3827-sec-0013}
---------------------------------------

The average coverage of samples was 55.31X‐2800X. Each variant labeled PASS had a quality value, ranging from 30.77 to 211,299. In total, 25 of 130 participants (19.2%, 25/130) carried genetic variants in the targeted genes. We identified 20 nonsynonymous single‐nucleotide variants (SNVs) in nine different genes, including 16 reported and four novel mutational sites. The most commonly mutated gene in our study was *SRD5A2* (52%, 13/25), followed by *AR* (24%, 6/25) and *PROKR2* (12%, 3/25) (OMIM 607,123). Three patients in our hypospadias cohort had variants in multiple targeted genes (*PROKR2/SRD5A2*, *PROKR2/AR*, *AR/TRIM17*). These observations contribute to the hypothesis that polygenic inheritance is a rare genetic cause of hypospadias. Moreover, a variant in *TRIM17* (OMIM 606,123) was identified for the first time in hypospadias patients. The genetic variants of all patients are shown in Table [2](#mgg3827-tbl-0002){ref-type="table"}.

###### 

Genetic variants identified by targeted NGS

  ID        Gene           Transcript    cDNA         Protein   Exon       GnomAD freq                  Genotype   Origin           ACMG
  --------- -------------- ------------- ------------ --------- ---------- ---------------------------- ---------- ---------------- ----------------------------
  P1        SRD5A2         NM_000348.3   c.G680A      p.R227Q   E4         0.006427                     Compound   Mother           P/PS3 PM1 PM2 PM3 PP4
  c.C16T    p.Q6X          E1            0.000175     Het       Father     P/PVS1 PM1 PM2 PP3 PP4                                   
  P2        SRD5A2         NM_000348.3   c.G680A      p.R227Q   E4         0.006                        Compound   Mother           P/PS3 PM1 PM2 PM3 PP4
  c.C16T    p.Q6X          E1            0.000175     Het       Father     P/PVS1 PM1 PM2 PP3 PP4                                   
  P3        SRD5A2         NM_000348.3   c.G607A      p.G203S   E4         0.00087                      Compound   Father           P/PS3 PM1 PM2 PM3 PP4
  c.C16T    p.Q6X          E1            0.000175     Het       De novo    P/PVS1 PM1 PM2 PM6 PP3 PP4                               
  P4        SRD5A2         NM_000348.3   c.G680A      p.R227Q   E4         0.006                        Compound   Mother           P/PS3 PM1 PM2 PP4 PP5
  c.T59C    p.L20P         E1            0.00005851   Het       Father     LP/PM2 PM3 PP3 PP4 PP5                                   
  P5        SRD5A2         NM_000348.3   c.G680A      p.R227Q   E4         0.006                        Compound   Father           P/PS3 PM1 PM2 PM3 PP4
  c.G607A   p.G203S        E4            0.00087      Het       Mother     P/PS3 PM1 PM2 PP4 PP5                                    
  P6        SRD5A2         NM_000348.3   c.G680A      p.R227Q   E4         0.006                        Compound   Mother           P/PS3 PM1 PM2 PM3 PP4
  c.G607A   p.G203S        E4            0.00087      Het       Father     P/PS3 PM1 PM2 PP4 PP5                                    
  P7        SRD5A2         NM_000348.3   c.G281T      p.R94M    E1         0.000                        Compound   Father           VUS/PM2 PP3 PP4
  c.G196A   p.G66R         E1            0.003        Het       Mother     VUS/PM2 PP3 PP4                                          
  P8        SRD5A2         NM_000348.3   c.C268T      p.H90Y    E1         0.000                        Compound   Mother           VUS/PM2 PP3 PP4
  c.G196A   p.G66R         E1            0.003        Het       Father     VUS/PM2 PP3 PP4                                          
  P9        SRD5A2         NM_000348.3   c.T59C       p.L20P    E1         0.0000585                    Compound   Father           LP/PM2 PM3 PP3 PP4 PP5
  c.C16T    p.Q6X          E1            0.000175     Het       Mother     P/PVS1 PM1 PM2 PP3 PP4                                   
  P10       SRD5A2         NM_000348.3   c.G680A      p.R227Q   E4         0.006                        Hom        Mother/father    P/PS3 PM1 PM2 PM3 PP4
  P11       SRD5A2         NM_000348.3   c.C736T      p.R246W   E5         0.000                        Compound   Father           P/PS3 PM1 PM2 PM3 PP4
  c.G680A   p.R227Q        E4            0.006        Het       Mother     P/PS3 PM1 PM2 PP3 PP4                                    
  P12       SRD5A2         NM_000348.3   c.C751T      p.P251S   E5         0.000                        Compound   Mother           LP/PM2 PM3 PP3 PP4
  c.G680A   p.R227Q        E4            0.006        Het       Father     P/PS3 PM1 PM2 PP4 PP5                                    
  PROKR2    NM_144773.3    c.G533C       p.W178S      E2        0.002597   Het                          Mother     LP/PS3 PM1 PP5   
  P13       SRD5A2         NM_000348.3   c.G607A      p.G203S   E4         0.00087                      Compound   Mother           P/PS3 PM1 PM2 PM3 PP4
  c.C16T    p.Q6X          E1            0.000175     Het       Father     P/PVS1 PM1 PM2 PP3 PP4                                   
  P14       AR             NM_000044.4   c.C2612T     p.A871V   E8         0.000                        Hem        Mother           P/PS3 PM1 PM2 PP4 PP5
  P15       AR             NM_000044.4   c.C2612T     p.A871V   E8         0.000                        Hem        Mother           P/PS3 PM1 PM2 PP4 PP5
  P16       AR             NM_000044.4   c.G1823A     p.R608Q   E3         0.000                        Hem        De novo          LP/PM1 PM2 PM6 PP3 PP4 PP5
  P17       AR             NM_000044.4   c.G1823A     p.R608Q   E3         0.000                        Hem        Mother           LP/PM1 PM2 PP3 PP4 PP5
  PROKR2    NM_144773.3    c.G533C       p.W178S      E2        0.002597   Het                          Mother     LP/PS3 PM1 PP5   
  P18       AR             NM_000044.4   c.G1789A     p.A597T   E3         0.000                        Hem        Na               P/PS3 PM1 PM2 PP4 PP5
  P19       AR             NM_000044.4   c.A173T      p.Q58L    E1         0.00015                      Hem        Mother           LP/PM1 PM2 PP3 PP4
  TRIM17    NM_001024940   c.C109T       p.R37X       E2        0.000      Het                          Father     VUS/PM2 PP3      
  P20       ZFPM2          NM_012082.3   c.A2107C     p.M703L   E8         0.000448                     Het        Mother           LP/PS3 PM2 PP4 PP5
  P21       PROKR2         NM_144773.3   c.G533C      p.W178S   E2         0.002597                     Het        Father           LP/PS3 PM1 PP5
  P22       BMP4           NM_001202.5   c.C751T      p.H251Y   E4         0.0001                       Het        Na               LP/PM1 PM2 PP3 PP5
  P23       CHD7           NM_017780.3   c.C2189T     p.T730I   E4         0.001                        Het        Na               VUS/PM2 PP3
  P24       HOXD13         NM_000523.3   c.G32C       p.G11A    E1         0.0008                       Het        Mother           LP/PS3 PM2 PP4 PP5
  P25       GLI3           NM_000168.5   c.C2110T     p.Q704X   E14        0.000                        Het        De novo          P/PVS1 PM1 PM2 PM6 PP3

Abbreviations: P, pathogenic; LP, likely pathogenic; VUS, variants of uncertain significance; NA, no related data; NGS, next‐generation sequencing.
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3.2. Diagnostic gene mutations {#mgg3827-sec-0014}
------------------------------

In total, we identified diagnostic gene mutations in 22 patients. The overall diagnostic yield of 16.9% (22/130) was generated by adding the pathogenic and LP variants according the ACMG guidelines (Figure [1](#mgg3827-fig-0001){ref-type="fig"}).

![Genetic variants identified by targeted next‐generation sequencing. Twenty‐five patients with genetic variants were identified, 22 of whom carried diagnostic variants](MGG3-7-e827-g001){#mgg3827-fig-0001}

Among these 21 diagnosed patients, nine showed compound heterozygous mutations, four had a heterozygous mutation, four had a hemizygous mutation, and only one had a homozygous mutation. Additionally, three patients had polygenic mutations. Eleven patients carried *SRD5A2* gene mutations and six patients harbored *AR* gene mutations. Five patients carried rare gene mutations in *ZFPM2*, *PROKR2* (OMIM 607,123), *BMP4* (OMIM 112,262), *HOXD13*, and *GLI3* (OMIM 165,240).

3.3. Clinical features of 130 patients {#mgg3827-sec-0015}
--------------------------------------

From the cohort, 130 patients presented hypospadias with varying degrees of severity, including 25 patients who manifested isolated hypospadias and 105 patients who had multiple hypospadias (with hypospadias accompanied by micropenis, cryptorchidism, and penoscrotal transposition).

3.4. Clinical features of patients with genetic variant {#mgg3827-sec-0016}
-------------------------------------------------------

Three types of external genital malformations were found in 25 patients, including hypospadias combined with micropenis (68%), hypospadias, micropenis combined with cryptorchidism (28%), and hypospadias combined with cryptorchidism (4%) (Figure [2](#mgg3827-fig-0002){ref-type="fig"}a). In addition, posterior hypospadias accounted for 52% of patients, middle hypospadias accounted for 36%, and anterior hypospadias accounted for 12% of patients (Figure [2](#mgg3827-fig-0002){ref-type="fig"}b). Hypospadias combined with micropenis was the most common malformation. However, all forms of posterior hypospadias, including the combined form, were the most common feature in patients with genetic mutations. Here, seven of 25 patients (28%) also showed thoracic spinal deformity, hydrocele, tricuspid regurgitation, inguinal hernia, tetralogy of Fallot, or finger deformities. Of note, none of the 25 patients had isolated hypospadias. The clinical phenotypes of the 25 patients with variants identified in the targeted genes are shown in Table [3](#mgg3827-tbl-0003){ref-type="table"}.

![The external genital phenotypes of patients with genetic variations. (a) Proportion of 25 patients in the phenotypic categories. (b) Proportion of hypospadias features among the 25 patients](MGG3-7-e827-g002){#mgg3827-fig-0002}

###### 

Clinical data of patients with genetic variants by gene‐targeted NGS

  ID                   Gene                        Age (years)   Classification    Complication   Inhibin B (pg/ml)   LH/FSH (mIU/ml)   T (ng/ml) (HCG stimulation test before /after)   DHT (pg/ml) (HCG stimulation test before /after)   T/DHT (HCG stimulation test after)   ther    
  -------------------- --------------------------- ------------- ----------------- -------------- ------------------- ----------------- ------------------------------------------------ -------------------------------------------------- ------------------------------------ ------- -------------------------------------------
  P1                   SRD5A2                      3.25          Perineal          Yes            No                  107.14            0.1/0.98                                         \<0.08/5.61                                        5.68/78.96                           71.0    No
  P2                   SRD5A2                      11.83         Proximal penile   Yes            No                  107.99            2.04/3.14                                        0.25/28                                            30.93/48.22                          58.1    No
  P3                   SRD5A2                      1.08          Proximal penile   Yes            No                  112.69            0.18/0.47                                        \<0.08/4.23                                        44.39/107.08                         39.5    No
  P4                   SRD5A2                      4.58          Proximal penile   Yes            No                  NA                NA                                               \<0.08/NA                                          12.99/NA                             NA      No
  P5                   SRD5A2                      4.25          Perineal          Yes            No                  NA                NA                                               NA                                                 NA                                   NA      No
  P6                   SRD5A2                      2.17          Proximal penile   Yes            Bilateral           157               NA                                               \<0.08/NA                                          14.24/NA                             NA      No
  P7                   SRD5A2                      7.92          Perineal          Yes            No                  NA                \<0.07/0.85                                      \<0.08/4.63                                        14.32/95.13                          48.7    No
  P8                   SRD5A2                      1.25          Proximal penile   Yes            No                  83.81             \<0.07/0.41                                      \<0.08/4.08                                        11.41/89.74                          45.5    No
  P9                   SRD5A2                      2.83          Scrotal           Yes            Bilateral           NA                \<0.07/0.58                                      \<0.08/2.31                                        5.85/37.72                           61.2    No
  P10                  SRD5A2                      2.1           Proximal penile   Yes            No                  70.17             \<0.07/0.46                                      0.12/1.29                                          19.11/17.76                          72.6    No
  P11                  SRD5A2                      13.58         Scrotal           Yes            No                  85.58             1.46/1.85                                        1.2/11.23                                          38.38/327.73                         34.3    No
  P12                  SRD5A2                      8.42          Penoscrotal       Yes            No                  49.65             \<0.07/1.16                                      \<0.08/1.69                                        18.80/57.55                          29.3    Thoracic spinal deformity
  PROKR2               Left hydrocele                                                                                                                                                                                                                                                    
  P13                  SRD5A2                      1.42          Perineal          Yes            Bilateral           NA                6.5/5.4                                          1.21/15.88                                         22.54/247.46                         64.2    Mild tricuspid regurgitation
  P14                  AR                          0.3           Coronal           Yes            no                  300.15            1.91/2.29                                        NA /1.25                                           NA /226.98                           5.5     No
  P15                  AR                          4.16          Scrotal           Yes            no                  72.78             \<0.07/1.18                                      \<0.08/1.69                                        12.25/290.42                         5.8     Right hydrocele penoscrotal transposition
  P16                  AR                          6.25          Proximal penile   Yes            Bilateral           37.3              0.13/1.47                                        \<0.08/1.68                                        18.10/152                            11.0    No
  P17                  AR                          9             Scrotal           Yes            No                  82.77             8.07/34                                          1.25/2.89                                          94.34/157.53                         18.3    Bilateral hydrocele
  PROKR2               Penoscrotal transposition                                                                                                                                                                                                                                         
  P18                  AR                          4.25          Perineal          Yes            Bilateral           NA                NA                                               NA                                                 NA                                   NA      Left inguinal hernia
  P19                  AR                          5             Scrotal           Yes            No                  28.67             \<0.07/0.49                                      \<0.08/2.02                                        8.3/76.66                            26.3    No
  TRIM17                                                                                                                                                                                                                                                                                 
  P20                  ZFPM2                       13.42         Scrotal           Yes            No                  74.46             0.6/3.64                                         0.55/NA                                            NA                                   NA      Tetralogy of Fallot
  P21                  PROKR2                      2.67          Coronal           Yes            Left                93.27             \<0.07/0.49                                      \<0.08/4.10                                        12.72/244.7                          16.7    No
  P22                  BMP4                        3.42          Midshaft          Yes            No                  NA                NA                                               NA                                                 NA                                   NA      No
  P23                  CHD7                        4.5           Midshaft          No             Right               NA                NA                                               NA                                                 NA                                   NA      No
  P24                  HOXD13                      11            Scrotal           Yes            No                  71.79             5.57/8.23                                        6.72/NA                                            394.22/NA                            NA      Penoscrotal transposition
  Breast development                                                                                                                                                                                                                                                                     
  P25                  GLI3                        5.83          Coronal           Yes            Bilateral           106.5             0.14/3.2 bilateral                               \<0.08/4.35                                        16.34/181.71                         23.94   Digital deformity

Microphallus: length of penis is more than 2.5 *SD* from the average penile length in males of matched age.

Abbreviations: NA, no related data; NGS, next‐generation sequencing; DHT, dihydrotestosterone; LH, luteinizing hormone; FSH, follicle stimulating hormone; HCG, human chorionic gonadotrophin.

John Wiley & Sons, Ltd

Serum testosterone (T) and DHT after human chorionic gonadotrophin (HCG) stimulation were measured in 17 patients. The T/DHT ratio (after HCG stimulation) of 10 patients with *SRD5A2* gene variants was above the normal threshold of 10, indicating that this ratio has positive predictive value in clinical diagnosis (Maimoun et al., [2011](#mgg3827-bib-0019){ref-type="ref"}). However, the T/DHT ratio was also higher than normal in three of five patients who were diagnosed with partial androgen insensitivity syndrome (PAIS). An elevated T/DHT ratio was observed in PAIS and among normal individuals. 5α‐reductase deficiency, therefore, cannot be diagnosed even if the T/DHT ratio is higher than normal. Instead, it is necessary to diagnose 5α‐reductase deficiency‐associated hypospadias by genetic sequencing.

4. DISCUSSION {#mgg3827-sec-0017}
=============

Hypospadias is a common feature related to undervirilization of the male external genitalia. The development of external genitalia and the urogenital tract is complex, involving multiple factors, including coordinated genetics, cellular differentiation, tissue interactions, enzyme activities, and hormonal mediation (Kalfa, Philibert, & Sultan, [2009](#mgg3827-bib-0016){ref-type="ref"}). The proper diagnosis of hypospadias is often challenging, given the significant heterogeneity of clinical presentations among patients with hypospadias. However, the diagnosis of hypospadias is important, and can facilitate sex assignment, selection of treatment strategies, and a more accurate evaluation of gonadal function. Here, we used a targeted NGS approach to identify 16 reported and four novel mutations in nine genes among 25 patients with various degrees of hypospadias.

*SRD5A2* encodes the steroid 5α‐reductase type 2 enzyme, which converts testosterone into DHT. In males, DHT induces the differentiation and growth of male external genitalia and development of secondary sexual characteristics during puberty (Yuan et al., [2017](#mgg3827-bib-0035){ref-type="ref"}). To date, over 130 different mutations throughout the five exons of *SRD5A2* have been reported (Human Gene Mutation Database, <http://www.hgmd.cf.ac.uk/ac/validate.php>). In our study, mutations in *SRD5A2* were the most common among those of the genes that were screened (52%, 13/25); this finding was consistent with that of previous study conducted in China (R. Wang et al., [2013](#mgg3827-bib-0033){ref-type="ref"}). These observations suggest that the *SRD5A2* is a hotspot for gene mutations in Han Chinese individuals with hypospadias. We identified nine different variants in 13 patients, including six previously reported variants (p.R246W, p.R227Q, p.G203S, p.G66R, p.L20P, p.Q6X) and three novel variants (p.P251S, p.R94M, p.H90Y). These mutations were clustered mainly in exons 1 and 4 (Figure [3](#mgg3827-fig-0003){ref-type="fig"}a). Three novel variants were predicted to have a damaging effect on enzyme function by two in silico prediction tools and were located in highly conserved regions (Figure [3](#mgg3827-fig-0003){ref-type="fig"}b). In addition, compound heterozygous mutations in the *SRD5A2* were identified in 12 of these patients (92.3%, 12/13). The p.R227Q variant was the most frequent variant (34.6%), followed by p.Q6X (19.2%) and p.G203S (15.4%), which is consistent with previous studies suggesting that these three variant positions are mutational hot spots in the Han Chinese population (Cheng et al., [2015](#mgg3827-bib-0012){ref-type="ref"}; Song, Fan, Zhao, & Gong, [2019](#mgg3827-bib-0026){ref-type="ref"}; Yuan et al., [2017](#mgg3827-bib-0035){ref-type="ref"}). The p.Q6X variant is a nonsense mutation occurring in exon 1, which presumably results in the formation of a drastically truncated protein and lack of several important functional regions. Specifically, five patients (P1, P2, P3, P9, P13) who carried a p.Q6X variant displayed relatively severe clinical manifestations, which may be related to the complete loss of enzyme activity. Therefore, residual enzyme activity may be associated with phenotypic severity.

![(a) Proportion of mutant alleles according to exon location. (b) Three novel variants in *steroid‐5‐α‐reductase 2* were identified among our patients, all of which affect a highly conserved residue](MGG3-7-e827-g003){#mgg3827-fig-0003}

Hypospadias is often caused by PAIS. This is an X‐linked recessive disorder caused by AR gene mutations (Su et al., [2017](#mgg3827-bib-0027){ref-type="ref"}). Testosterone and DHT both bind the AR to activate a transcriptional response within the developing male external genitalia (Matsushita et al., [2018](#mgg3827-bib-0020){ref-type="ref"}). In our cohort of patients, *AR* had the second highest number of all variants (24%, 6/25), with four different variants (p.Q58L, p.A597T, p.R608Q, and p.A871V) identified. These variants have all been previously reported and are distributed among multiple *AR* functional regions: two in the ligand binding domain (LBD), three in the DNA binding domain (DBD), and one in the amino‐terminal transactivation domain (NTD). The p.A871V variant located in the LBD could lead to PAIS or mild AIS according to previous studies (Gottlieb, Beitel, Nadarajah, Paliouras, & Trifiro, [2012](#mgg3827-bib-0015){ref-type="ref"}). Two patients (P14 and P15) who carried the p.A871V variant were diagnosed with PAIS; however, the clinical phenotype of the latter is more severe. Patients in our study with identical AR mutations were observed to display different phenotypes, which may have resulted from somatic mosaicism or other factors, such as genetic background or co‐regulatory factors involved in the pathogenesis or phenotype of PAIS. In addition, three patients (P16, P17, and P18) carried *AR* mutations in the DBD and presented with PAIS, which is consistent with a previous report suggesting that *AR* mutations in the DBD region may directly underlie PAIS (Giwercman, Ivarsson, Richthoff, Lundin, & Giwercman, [2004](#mgg3827-bib-0014){ref-type="ref"}). The p.Q58L variant located in the NTD was previously reported to be associated with male infertility and various degrees of hypospadias (Akcay et al., [2014](#mgg3827-bib-0001){ref-type="ref"}; Kalfa et al., [2013](#mgg3827-bib-0017){ref-type="ref"}). In addition to a p.Q58L variant in the *AR* gene, P19 also carried a heterozygous p.R37X variant in *TRIM17*. P19 presented with posterior hypospadias, microphallus, and testicular dysgenesis; long‐term follow‐up is needed to determine whether fertility will be affected in this patient. *TRIM17*, a member of the RING finger family, is expressed in the testis during embryonic development (Reymond et al., [2001](#mgg3827-bib-0022){ref-type="ref"}). No *TRIM17* gene mutation has been previously found in hypospadias patients. We cannot determine conclusively whether the clinical phenotype of P19 is related to *TRIM17* gene mutation; thus, further studies are needed to clarify this case.

*PROKR2* is related to isolated hypogonadotropic hypogonadism (IHH) and Kallmann syndrome (KS), which is an autosomal dominant trait. The p.W178S variant of *PROKR2* was identified in three patients, two of them (P12 and P17) with mutations in multiple genes, carrying *SRD5A2* and *AR* gene mutations, respectively. The p.W178S variant has been previously reported in Chinese patients, and according to a functional assay, it is associated with markedly reduced expression and protein instability (Monnier et al., [2009](#mgg3827-bib-0021){ref-type="ref"}; Y. Wang, Gong, Qin, Liu, & Tian, [2017](#mgg3827-bib-0034){ref-type="ref"}). It is interesting to identify IHH/KS‐related pathogenic gene mutations in patients with hypospadias in our study, but these patients are too young to be diagnosed with IHH. It is worth noting that patients P12 and P17 are characterized by posterior hypospadias, especially P17, who showed penoscrotal transposition. It is possible that there are variants in genes controlling penile development in addition to *PROKR2* gene variations. Patient P21 displayed coronal hypospadias which could presumably involve additional undetected variants in genes controlling penile development or gene variations resulting from environmental factors.

*ZFPM2* (also known as *FOG2*) is co‐expressed with *GATA4* in the heart, brain, and gonads. *ZFPM2* has been demonstrated to regulate, with *SF‐1* and *GATA4*, the expression of other key genes for sex determination or differentiation, including *SOX9* and *AMH*(Bashamboo et al., [2014](#mgg3827-bib-0003){ref-type="ref"}). Mutations in *ZFPM2* have commonly been shown to be associated with congenital heart disease; however, they have only recently been detected in individuals with hypospadias (Eggers et al., [2016](#mgg3827-bib-0013){ref-type="ref"}). A heterozygous missense variant p.M703L in *ZFPM2* was detected in patient P20, who presented with Tetralogy of Fallot, posterior hypospadias, and micropenis. The p.M703L variant found in our study has been previously reported as a pathogenic variant in congenital heart disease, although it has not been reported to be associated with hypospadias (Tan, Huang, Xu, Yang, & Yang, [2012](#mgg3827-bib-0028){ref-type="ref"}; Zhang et al., [2014](#mgg3827-bib-0036){ref-type="ref"}). The p.M703L variant is located in the sixth zinc finger structure. The first and sixth zinc finger structures of *ZFPM2* interact with conserved sequences in the N‐terminal zinc finger of mammalian *GATA4*. Therefore, the p.M703L mutation may impair the gonadal development pathway initiated by the *GATA4‐ZFPM2* complex by affecting the binding of *ZFPM2* to *GATA4*(Brennan & Capel, [2004](#mgg3827-bib-0007){ref-type="ref"}).

*BMP4* is a member of the BMP family, which plays a vital role in embryonic development, including the regulation of the signaling cascades involved in urethral development. A heterozygous missense variant p.H251Y in *BMP4* was detected in patient P22, who presented with middle hypospadias and microphallus. The p.H251Y variant is located in the precursor peptide region of *BMP4*, which may affect the maturation and function of the whole protein. This missense variant of *BMP4* has been reported in Chinese patients with hypospadias in previous studies (T. Chen et al., [2007](#mgg3827-bib-0010){ref-type="ref"}; H. Wang et al., [2018](#mgg3827-bib-0032){ref-type="ref"}).

*CHD7* is related to CHARGE syndrome or KS, which is of autosomal dominant inheritance. Several studies have found that not all patients carrying SNVs in *CHD7* develop the classical CHARGE syndrome phenotype (Van Nostrand et al., [2014](#mgg3827-bib-0031){ref-type="ref"}). In our study, one *CHD7* heterozygous missense p.T730I variant was detected in patient P23, who presented with middle hypospadias and right cryptorchidism. However, no other malformations were consistent with the clinical diagnosis of CHARGE syndrome. Thus, according to ACGM guidelines, this is a VUS. However, this site is located in the SANT domain, which is highly conserved (Boyer, Latek, & Peterson, [2004](#mgg3827-bib-0005){ref-type="ref"}). This region may be a histone tail binding module, which can bind to DNA or modified histones. In this case, we cannot establish whether the phenotype is related to the *CHD7* variants or an atypical phenotype associated with these gene variants.

The *HOXD13* is related to hypoplastic synpolydactyly and hypospadias. The *HOXD13* is expressed in the mesenchyme of the GT, and plays a major role in the development of the external genitalia and limbs (Tüzel et al., [2007](#mgg3827-bib-0029){ref-type="ref"}). The p.G11A heterozygous mutation in *HOXD13* was found in patient P24, who presented posterior hypospadias and penoscrotal transposition. In vitro studies have shown that the p.G11A mutation causes a significant reduction in protein half‐life (Brison et al., [2012](#mgg3827-bib-0008){ref-type="ref"}). In combination with previous studies, it was found that males with *HOXD13* gene heterozygous mutations generally had milder limb deformities, some of whom also had mild hypospadias. However, patient P24 presented scrotal hypospadias, penoscrotal transposition, and breast development during puberty. The phenotypic diversity of *HOXD13* heterozygous variants could be attributed to incomplete penetrance and variable expressivity of autosomal dominant inheritance.

*GLI3* is a transcription factor and is a downstream targets of the sonic hedgehog pathway during limb and craniofacial development. It may also be related to urethral and genital development. Several SNPs in the *GLI3* in Californian patients with hypospadias have been associated with increased risk of hypospadias (Carmichael et al., [2013](#mgg3827-bib-0009){ref-type="ref"}). We identified a p.Q704X heterozygous mutation in *GLI3* in patient P25, who presented with coronal hypospadias, micropenis, bilateral cryptorchidism, and digital deformity. To our knowledge, the current study is the first to identify a *GLI3* gene mutation in a patient with hypospadias, which provides a possible association between *GLI3* and urethral development.

5. CONCLUSIONS {#mgg3827-sec-0018}
==============

In summary, we performed targeted NGS of 105 genes associated with the molecular regulation of external genitalia and urogenital tract development in 130 patients with hypospadias of unknown etiology. A total of 25 patients (19.2%) were found to carry genetic variants in one or more of the nine targeted genes. Twenty‐two (16.9%) had diagnostic variants.

The diagnostic rate observed in our study is lower than that observed in other studies (Eggers et al., [2016](#mgg3827-bib-0013){ref-type="ref"}; H. Wang et al., [2018](#mgg3827-bib-0032){ref-type="ref"}). Possible reasons include: (a) the panel of this study contains 105 genes, and may have discounted some variant genes or mutations in regulatory regions; (b) the criteria for selecting patients are different; in order to study the genetic factors affecting hypospadias development, the phenotype of hypospadias patients was not strictly screened in this study. Among 130 patients, 25 patients had hypospadias without genetic variation. In addition, the clinical phenotype of hypospadias in some patients is mild, and the probability of gene mutation in these patients is low; (c) the positive rate of gene mutations may be different for patients of different races; (d) this study did not detect DNA copy number variations.

In conclusion, we identified the precise molecular etiology for several patients in our cohort. The most frequently mutated gene in our study was *SRD5A2* (52%, 13/25), followed by *AR* (24%, 6/25). Although the contribution of variants in the other seven candidate genes is not high, it cannot be ignored. Hypospadias combined with micropenis accounted for 68% of all patients, which may represent a significant clinical sign for genetic detection. Specifically, combined with previous studies, we speculate that oligogenicity may be a rare genetic cause of hypospadias. Genetic diagnosis is useful for patients and clinicians alike. It contributes to the clinical understanding of hypospadias, and is invaluable for the genetic counseling of couples contemplating future pregnancies.
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